Back to front
Section

Business

Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.

UBS lifts Caterpillar price target to $900 while keeping a Neutral stance
The Apex Times

THE APEX TIMES

More Stories

Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing
The Apex Times

THE APEX TIMES

Business / The Apex Times

Pfizer’s berobenatide data sharpen the pitch for monthly GLP-1 obesity dosing

At the American Diabetes Association meeting, Pfizer highlighted Phase 2b results for PF’3944 (berobenatide), an ultra-long-acting GLP-1 receptor agonist designed for once-monthly maintenance dosing - along with early tolerability outlines that will shape how investors weigh Pfizer’s obesity push.

Jun 7, 1:22 AM EDT